Abstract
Time-kill studies, even those performed with in vitro dynamic models, often do not provide definitive comparisons of different antimicrobial agents. Also, they do not allow determinations of equiefficient doses or predictions of area under the concentration-time curve (AUC)/MIC breakpoints that might be related to antimicrobial effects (AMEs). In the present study, a wide range of single doses of trovafloxacin (TR) and twice-daily doses of ciprofloxacin (CI) were mimicked in an in vitro dynamic model. The AMEs of TR and CI against gram-negative bacteria with similar susceptibilities to both drugs were related to AUC/MICs that varied over similar eight-fold ranges [from 54 to 432 and from 59 to 473 (microg . h/ml)/(microg/ml), respectively]. The observation periods were designed to include complete bacterial regrowth, and the AME was expressed by its intensity (the area between the control growth in the absence of antibiotics and the antibiotic-induced time-kill and regrowth curves up to the point where viable counts of regrowing bacteria equal those achieved in the absence of drug [IE]). In each experiment monoexponential pharmacokinetic profiles of TR and CI were simulated with half-lives of 9.2 and 4.0 h, respectively. Linear relationships between IE and log AUC/MIC were established for TR and CI against three bacteria: Escherichia coli (MIC of TR [MICTR] = 0.25 microg/ml; MIC of CI [MICCI] = 0.12 microg/ml), Pseudomonas aeruginosa (MICTR = 0.3 microg/ml; MICCI = 0.15 microg/ml), and Klebsiella pneumoniae (MICTR = 0.25 microg/ml; MICCI = 0.12 microg/ml). The slopes and intercepts of these relationships differed for TR and CI, and the IE-log AUC/MIC plots were not superimposed, although they were similar for all bacteria with a given antibiotic. By using the relationships between IE and log AUC/MIC, TR was more efficient than CI. The predicted value of the AUC/MIC breakpoint for TR [mean for all three bacteria, 63 (microg . h/ml)/(microg/ml)] was approximately twofold lower than that for CI. Based on the IE-log AUC/MIC relationships, the respective dose (D)-response relationships were reconstructed. Like the IE-log AUC/MIC relationships, the IE-log D plots showed TR to be more efficient than CI. Single doses of TR that are as efficient as two 500-mg doses of CI (500 mg given every 12 h) were similar for the three strains (199, 226, and 203 mg). This study suggests that in vitro evaluation of the relationships between IE and AUC/MIC or D might be a reliable basis for comparing different fluoroquinolones and that the results of such comparative studies may be highly dependent on their experimental design and datum quantitation.
MeSH Terms
Anti-Infective Agents/pharmacokinetics,pharmacology
Bacteria/drug effects,growth & development
Ciprofloxacin/pharmacokinetics,pharmacology
Dose-Response Relationship, Drug
Fluoroquinolones
Humans
Microbial Sensitivity Tests
Naphthyridines/pharmacokinetics,pharmacology
Chemicals
Anti-Infective Agents
Fluoroquinolones
Naphthyridines
Ciprofloxacin
trovafloxacin
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Firsov A A
Department of Pharmacokinetics, Centre of Science & Technology LekBioTech, Moscow 117246, Russia. Biotec@glas.apc.org
Vostrov S N
Shevchenko A A
Portnoy Y A
Zinner S H
References (25)
25 references, click to expand
-
Influence of ampicillin elimination half-life on in-vitro bactericidal effect.
J Antimicrob Chemother. 1985 Jan;15 Suppl A:257-60
PMID: 3980329
-
Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept.
Antimicrob Agents Chemother. 1998 Mar;42(3):659-65
PMID: 9517948
-
The comparative pharmacokinetics of five quinolones.
J Antimicrob Chemother. 1986 Nov;18 Suppl D:71-81
PMID: 3468102
-
In vitro models for the study of antibiotic activities.
Prog Drug Res. 1987;31:349-81
PMID: 3326034
-
Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model.
Antimicrob Agents Chemother. 1990 Jul;34(7):1312-7
PMID: 2117416
-
Antibacterial activity of cefpodoxime proxetil in a pharmacokinetic in-vitro model.
J Antimicrob Chemother. 1990 Jul;26(1):71-9
PMID: 2211449
-
Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin.
DICP. 1991 Oct;25(10):1050-7
PMID: 1803788
-
In vitro simulated pharmacokinetics profiles: forecasting antibiotic optimal dosage.
Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:406-9
PMID: 1820913
-
Pharmacokinetic considerations in quinolone therapy.
Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):34S-38S
PMID: 8474936
-
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.
Antimicrob Agents Chemother. 1993 May;37(5):1073-81
PMID: 8517694
-
Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
Antimicrob Agents Chemother. 1993 Nov;37(11):2454-8
PMID: 8285633
-
Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.
Antimicrob Agents Chemother. 1994 Dec;38(12):2702-9
PMID: 7695250
-
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers.
J Antimicrob Chemother. 1995 Aug;36(2):385-94
PMID: 8522468
-
Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
Drugs. 1995;49 Suppl 2:194-6
PMID: 8549301
-
Pharmacodynamics of quinolones.
Drugs. 1995;49 Suppl 2:197-9
PMID: 8549302
-
Comparison of the pharmacodynamic properties of quinolones.
Drugs. 1995;49 Suppl 2:269-71
PMID: 8549328
-
In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.
Antimicrob Agents Chemother. 1995 Oct;39(10):2210-6
PMID: 8619569
-
A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa.
J Antimicrob Chemother. 1996 Apr;37(4):703-10
PMID: 8722536
-
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
Antimicrob Agents Chemother. 1996 Jan;40(1):47-9
PMID: 8787877
-
Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Antimicrob Agents Chemother. 1996 Mar;40(3):627-32
PMID: 8851583
-
Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.
Antimicrob Agents Chemother. 1996 Mar;40(3):734-8
PMID: 8851602
-
Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.
Antimicrob Agents Chemother. 1997 Jun;41(6):1281-7
PMID: 9174184
-
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
J Antimicrob Chemother. 1997 Jun;39 Suppl B:43-9
PMID: 9222069
-
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
J Antimicrob Chemother. 1997 Nov;40(5):639-51
PMID: 9421311
-
Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
Antimicrob Agents Chemother. 1985 Mar;27(3):375-9
PMID: 3158275